Bulletin
Investor Alert

New York Markets After Hours

Dec. 2, 2021, 3:20 a.m. EST

Lymphoma Treatment Market Report 2021-26: Industry Trends, Size, Share, Analysis and Forecast

Lymphoma Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Abbott Laboratories (ABT)
  • X
    Bristol Myers Squibb Co. (BMY)
  • X
    Eli Lilly & Co. (LLY)

or Cancel Already have a watchlist? Log In

Dec 02, 2021 (Heraldkeepers) -- According to IMARC Group's latest report, the global lymphoma treatment market grew at a CAGR of around 8% during 2015-2020. Looking forward, the market is expected to continue its moderate growth during 2021-2026.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Lymphoma stands for a type of cancer that affects the lymphatic system and impairs the body’s immune response. It targets the lymphocytes or white blood cells in the lymph nodes, bone marrow, thymus, and spleen. Lymphoma causes swelling in the lymph nodes, weight loss, fatigue, high fever, and dyspnea. The two main types of this disease are Hodgkin and non-Hodgkin lymphoma. Some common lymphoma treatments include chemotherapy, radiation therapy, bone marrow transplant, active surveillance, monoclonal antibody therapy, immunotherapy drugs, etc.

Request Free Sample Report: https://www.imarcgroup.com/lymphoma-treatment-market/requestsample

Market Trends

A significant growth in the healthcare sector, coupled with the increasing geriatric population, who are more prone to lymphoma, are also augmenting the global market. Additionally, rising consumer health awareness and the emergence of innovative treatment alternatives and diagnostic technologies, such as immune checkpoint inhibitors, are also augmenting the market growth. Several healthcare centers and hospitals are getting inclined towards advanced imaging technologies, such as Magnetic Resonance Imaging (MRI), computed tomography (CT), and positron emission tomography (PET) scans for timely detection and respective treatment of cancer cells. Moreover, the rising investments in extensive research and development activities in the healthcare industry are further expected to bolster the global market for lymphoma treatment in the coming years.

Ask Analyst and Browse Full Report with TOC & List of Figure: https://bit.ly/30F3Vb6

List of Key Companies Covered in this Market Report:

Abbott Laboratories /zigman2/quotes/203724446/composite ABT -0.41%
Bristol-Myers Squibb Company /zigman2/quotes/202559280/composite BMY -0.26%
Eli Lilly and Company /zigman2/quotes/200106384/composite LLY -0.82%
Hoffmann-La Roche Ltd (swx:RO)
Johnson & Johnson /zigman2/quotes/201724570/composite JNJ -0.31%
Merck & Co. Inc. /zigman2/quotes/209956077/composite MRK -0.31%
Novartis AG (swx:NOVN)
Spectrum Pharmaceuticals /zigman2/quotes/205199409/composite SPPI +1.90%
Takeda Pharmaceutical Company Ltd (tyo:4502)
Teva Pharmaceutical Industries Ltd (tlv:TEVA)

The report has segmented the market on the basis of type, test type, drug and geography

Breakup by Type:

Hodgkin Lymphoma
Non-Hodgkin Lymphoma

Breakup by Test Type:

Chemotherapy
Radiation Therapy
Immunotherapy
Targeted Therapy
Biologic Therapy
Others

Breakup by Drug:

Adcetris
Rituxan
Opdivo
Imbruvica
Keytruda
Revlimid
Others

Breakup by Geography:

/zigman2/quotes/203724446/composite
US : U.S.: NYSE
$ 126.05
-0.52 -0.41%
Volume: 4.00M
Jan. 19, 2022 4:02p
P/E Ratio
31.19
Dividend Yield
1.49%
Market Cap
$223.81 billion
Rev. per Employee
$388,147
loading...
/zigman2/quotes/202559280/composite
US : U.S.: NYSE
$ 64.72
-0.17 -0.26%
Volume: 12.56M
Jan. 19, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
3.34%
Market Cap
$144.03 billion
Rev. per Employee
$1.50M
loading...
/zigman2/quotes/200106384/composite
US : U.S.: NYSE
$ 245.05
-2.02 -0.82%
Volume: 2.49M
Jan. 19, 2022 4:02p
P/E Ratio
37.41
Dividend Yield
1.60%
Market Cap
$236.35 billion
Rev. per Employee
$793,100
loading...
/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 166.58
-0.52 -0.31%
Volume: 5.93M
Jan. 19, 2022 4:00p
P/E Ratio
24.90
Dividend Yield
2.55%
Market Cap
$439.91 billion
Rev. per Employee
$679,695
loading...
/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 81.29
-0.25 -0.31%
Volume: 11.19M
Jan. 19, 2022 4:03p
P/E Ratio
28.70
Dividend Yield
3.40%
Market Cap
$205.97 billion
Rev. per Employee
$660,851
loading...
/zigman2/quotes/205199409/composite
US : U.S.: Nasdaq
$ 1.07
+0.02 +1.90%
Volume: 3.37M
Jan. 19, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$185.28 million
Rev. per Employee
N/A
loading...
1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.